IL-31

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Retrieved on: 
Thursday, February 29, 2024
Research, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Cosmetics, Retail, Science, Other Science, Adapalene, Education, Investment, Growth, Calcineurin, Skin, Database, STAR, FY, Aesthetics, Acne, Sculptra, Prurigo nodularis, Defense, FACE, European Medicines Agency, Council, Congress, Pimple, GAIN, Atopic dermatitis, Sleep, ESG, Benzoyl peroxide, George Washington University, American Academy, Marketing, Health Canada, Core, Patient satisfaction, FDA, Quality of life, Ageing, Food, IL-31, Risk, AAD, Patient, Restylane, Pharmaceutical industry

2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.

Key Points: 
  • 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
  • On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
  • Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
  • In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.

CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023

Retrieved on: 
Monday, October 23, 2023
Ethnographic Museum of the University of Zurich, Patient, American College, IL-31, Itch, UDCA, The Duke of Edinburgh's International Award - Canada, Hope, Pathology, Conditional sentence, NRS, Liver, ALP, American College of Gastroenterology, HIV disease progression rates, PBC, Ursodeoxycholic acid, Risk, European Association for the Study of the Liver, Research and development, Cholestatic pruritus, Alkaline phosphatase, Primary biliary cholangitis, University, EASL, Cholestasis, Atopic dermatitis, Therapy, Doctor of Philosophy, Pharmaceutical industry, Research, MD

VANCOUVER, British Columbia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced today the presentation of findings from its post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC), showing baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31. The presentation, named the recipient of this year’s International Award by the American College of Gastroenterology, will be presented by Professor Andreas E. Kremer, MD, Ph.D., MHBA, a leading authority in cholestatic pruritus from the University of Zurich. Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.

Key Points: 
  • Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.
  • The data were previously presented at the European Association for the Study of the Liver (EASL)’s The International Liver Congress™ 2023 in Vienna, Austria.
  • “These results offer a glimmer of hope in that they link IL-31 levels in patients with PBC to itch.
  • Elevated risk due to ELF was identified in 43.2% of patients who currently meet guidelines for second-line treatment vs. 27.2% within patient groups not recommended for second-line treatment.

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

Retrieved on: 
Monday, May 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, IL-31, Sleep, Quality of life, SAD, Atopic dermatitis, Inflammation, Trial of the century, Patient, European, Numabe Station, MAD, Itch, AD, Skin, Disease, Vaccine, Pharmaceutical industry

Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).
  • The first subject dosing marks the beginning of a combined single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a/1b clinical study, conducted in collaboration with Numab’s Asia-regional partner Kaken Pharmaceutical.
  • The study will enroll non-Asian and Japanese healthy volunteers in the SAD sub-study and moderate-to-severe AD patients in the MAD sub-study.
  • While standard of care blocks IL-4 and IL-13, NM26-2198 blocks IL-31 in addition, thereby specifically targeting the neuroinflammatory pathway that causes itch.

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Retrieved on: 
Tuesday, September 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PAKT, Research, Professor, Rosacea, KA, Science, Frontiers of Medicine, Congress, AM, Population, IL-31, Thought, Patient, Genetics, RESEARCH, Atopic dermatitis, Sensitive, Woman, Prurigo nodularis, Adapalene, Partnership, Chairperson, Skin, Investment, Acne, Acquisition, Prurigo, Benzoyl peroxide, European Academy of Management, Nervous system, Cetaphil, Onychomycosis, Diagnosis, PM, Perkinsus marinus, Nail, Pharmaceutical industry, Cosmetics, Sculptra, Trifarotene, Methyl aminolevulinate, Ivermectin, Adapalene/benzoyl peroxide, Venereology, Galderma, Dermatology

Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.

Key Points: 
  • Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022.
  • As the pure-play dermatology leader, Galdermas significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
  • Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
  • EADV congress to exchange information, share insights and
    GLOBAL HEAD OF RESEARCH & DEVELOPMENT, GALDERMA
    Below is a full list of activities taking place.

Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Retrieved on: 
Monday, December 6, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Patient, Skin, Neuron, Prurigo nodularis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IL-31, Breakthrough therapy, Genome, Partnership, Dermatology, Gene expression, Inflammation, Transcriptomics technologies, Bajaj Consumer Care, Systematic review, Itch, Atopic dermatitis, Extracellular matrix, The Journal of Allergy and Clinical Immunology, RNA, FDA, Journal, Disease, Nemolizumab, Food, Pharmaceutical industry, Medical device, Vaccine

Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level.

Key Points: 
  • Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level.
  • These data emphasize that nemolizumab may have a key role to play for patients with moderate to severe PN.
  • PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
  • Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 worldwide except Japan and Taiwan.

Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL® at the 2021 EADV Congress

Retrieved on: 
Tuesday, September 28, 2021
Biotechnology, Pharmaceutical, General Health, Health, Fitness & Nutrition, Cosmetics, Retail, Other Health, Consensus, Cream, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Prurigo, Population, Doxycycline, Breakthrough therapy, Consultant, Â, Prurigo nodularis, Union, Safety, Consensus decision-making, Rosacea, Industry, Neuron, Acne, Food, Disease, Bajaj Consumer Care, Onychomycosis, Q&A, Itch, CHC, Nicotinamide, Partnership, Prevalence, Risk, European Academy of Management, Inflammation, FDA, Systematic review, IL-31, Method, Face, Congress, Moisturizer, Diagnosis, Patient, Comedo, Atopic dermatitis, European Union, Research, PN, Pharmaceutical industry, Sulfur, Vaccine, Cosmetics, Medical device, Agriculture, Fused quartz

The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis.

Key Points: 
  • The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis.
  • Galderma will also showcase its latest acne treatment, AKLIEF (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.
  • Visitors will be able to explore highlights from the CETAPHIL portfolio of 61 products and the largest update in the brands 70-year history.
  • Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio.